Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AcSé-ESMART molecularly stratified pediatric relapsed or refractory cancer trial
2024-514791-40-00Phase 2Authorised
- Sponsor
- Gustave Roussy
- Start
- Aug 2016
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 7
01
Overview
Phase 2, open-label trial of vinorelbine, temozolomide, enasidenib, capmatinib, capivasertib and 4 more in childhood cancer, Non-hematologic malignancy and hematopoietic malignancies (10 arms), sponsored by Gustave Roussy. Primary endpoint: Recommended phase II dose. Planned start Aug 2016; status: authorised.
02
Drugs
vinorelbinetemozolomideenasidenibcapmatinibcapivasertib
03
Conditions
childhood cancerNon-hematologic malignancyhematopoietic malignancies
Beyond the preview
Go deeper on 2024-514791-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514791-40-00.